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osting by EAbstract The strategy of World Health Organization is to develop efﬁcient and inexpensive vac-
cine against various infectious diseases amongst children’s population. Vaccination is considered
as the most cost effective health intervention known to public. Since 90 years various substances
have been added in vaccine formulation but still alum is considered as the safest adjuvant for
human use licensed by United States Food and Drug Administration. MF 59 and ASO4 are the
adjuvants were developed recently and approved for human use. Due to poor adjuvancity, conven-
tional vaccines require multiple recall injection at approximately time intervals to attain optimal
immune response. For past approximately two decades the vaccine research has been focused
towards the alternation of alum type of adjuvant in order to increase the immunogenicity. The
development of new vaccines, is more efﬁcacious or easier to deliver, or both have become an area
of research that can certainly beneﬁt from controlled release technology. Especially, the conversion
of multiple administration vaccine into single administration vaccine may represent an improved
advancement towards the betterment of human health care and welfare. Biodegradable polymer
microparticles have been evaluated for delivering antigens in native form, sustained release keeping
in mind the safety aspects. In this article we review the overall concept of adjuvants in vaccine tech-
nology with special focus towards the prospects of controlled release antigens.
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Vaccines are considered as one of the most successful medical
inventions against various infectious diseases (Hilleman, 2000).
In 1974, the World Health Organization (WHO) ofﬁcially
launched a global immunization programme called Expanded
Programme on Immunization (EPI). The ultimate aim of EPI
was to protect the child population across the globe against
vaccine preventable diseases in general and particularly diph-
theria, whooping cough, tetanus, polio, tuberculosis and mea-
sles by the year 2000. Particular in the year 1984, World Health
Organization established the uniform vaccine schedule for
diphtheria, whooping cough, tetanus, polio, tuberculosis and
measles. The high proportion of chronic infection that is ac-
quired during childhood can be prevented by routine infant
immunization programme.
The Expanded Programme on Immunization is now re-
named as Universal Immunization Programme (UIP). The
EPI was launched in 1978 in India after successful global erad-
ication of small pox in 1975 through effective vaccination pro-
grammes and strengthened surveillance. The WHO global
advisory group of Expanded Programme on Immunization
in the year 1991 recommended that by the year 1997, accord-
ingly, hepatitis B vaccine should be introduced into national
immunization programme across countries around the globe
because of high rate of incidence of chronic infectious diseases
that could affect during childhood by hepatitis B virus.
Accordingly, this vaccine (hepatitis B) has been included in
the national immunization programme in more than 130 coun-
tries (Kane, 1998). Later, yellow fever and Haemophilus inﬂu-
enzae meningitis (Hib) vaccines have been added in countries
with a high burden of disease (Fiore et al., 2009).
Vaccine development and immunization constitute critical
component of public health policy in any nation. Accordingly,
the Global Programme for Vaccines and Immunization (GPV)
was established in 1994 and this programme thus had the terms
of orientation that span from vaccine research through vaccine
production and quality control to help policy matter of health
plan and provide their services to control vaccine preventable
diseases. The Children’s Vaccine Initiative (CVI) is a compan-
ion organization to the Global Programme for Vaccines andImmunization and has its own strategic plan. The purpose of
CVI is to develop new technologies to progress and develop
a single shot efﬁcient vaccine. It should be given as a single
dose (preferably by oral). It is effective when administered near
birth, heat stable, contains multiple antigens and highly effec-
tive against wide variety of diseases. With a particular focus on
the world BPL (below poverty line) children, GPV aims at
strengthening routine immunization services, increasing wide
coverage and introducing novel generic vaccines. Global Alli-
ance for Vaccines and Immunization (GAVI), an advisory
group comprising National Governments and International
agencies such as WHO, World Bank, UNICEF and industries
was launched on January, 2000. GAVI’s mission statement is
‘‘To save children’s lives and protect people’s health through
wide spread use of vaccines with a particular emphasis on
developing countries’’. As an alliance of major leaders in Inter-
national health and development, GAVI has great potential in
decision making among policy makers and donors on the value
of vaccination for reducing poverty and infant mortality in the
developing countries.
The decision to introduce a vaccine into EPI is greatly inﬂu-
enced by a number of factors such as bio-burden, epidemiolog-
ical aspects with special reference to transmission, vaccine
factors that include safety, efﬁcacy and availability, feasibility
of introduction, ﬁnancial implications and projected or ex-
pected beneﬁts in terms of morbidity, mortality and cost effec-
tiveness. Thus a vaccine that is ideal for introduction in to EPI
would be one that is highly efﬁcacious, economical, safe and
protects against disease. Therefore, in designing effective vac-
cines certain key elements are essential such as:
1. An antigen that can stimulate good immune response.
2. Presentation of antigens in order to augment the immune
response.
3. Presentation of antigens in native form.
Stimulation of innate immune system is an important role
in the evolution of adaptive immune response (Hobe et al.,
2004). Therefore, inclusion of immune potentiators (adju-
vants), which triggers a robust and long lasting immune re-
sponse, is of primary importance.
Vaccine adjuvants – Current status and prospectson controlled release adjuvancity 1992. What are adjuvants and their status?
The ultimate principle of vaccination is to generate a strong
immune response against infectious diseases. Adjuvant is a
term coined from the Latin word adjuvare, which means to
help or to augment. A vaccine adjuvant is a component that
can improve the effectiveness of vaccines by inducing robust
immune responses (Vogel, 1998). Therefore, traditionally,
adjuvants have been used for vaccine formulations by the
industries in order to augment the immune response. The con-
cept of adjuvants was ﬁrst focused by Ramon (1925, 1926)
emerged from observations that an abscess at the inoculation
site produced higher speciﬁc antibody titers. Generally, adju-
vants can be used for various purposes (Aguilar and
Rodriguez, 2007):
1. To augment the immune response of any antigens by deliv-
ering in native form.
2. To reduce the multiple immunization protocol for protec-
tive immunity. In particular to develop single step vaccina-
tion coverage that can reduce the vaccination costs.
3. To enhance the immune response of immune compromised
adults and weakened immune system of children, to elicit
cytotoxic T lymphocytes response and generate local
immune response (Achal et al., 2005).
During the last 90 years many adjuvants have been devel-
oped among them aluminum and calcium salts are licensed
for human use (Achal et al., 2005). But recently MF 59 and
ASO4 have been approved for human use (Tagliabue and
Rappuoli, 2008) being considered as the adjuvants of the
new era of vaccinology. Because of higher toxicity no other
adjuvants have been licensed for human vaccination pro-
gramme. Since the safety of adjuvant is the prime importance
for routine vaccination, Edelman (1980) listed various criteria
such as general toxicity, hypersensitivity reactions, carcinoge-
nicity, teratogenicity, etc. Therefore, the ideal adjuvant would
be non-toxic, biodegradable, cheap, non-immunogenic by itself
and must not have any interaction with the antigen.
2.1. Types of adjuvants
There are several types of adjuvants with differing modes of
action. These include mineral salts, oil emulsions, immune
stimulating complexes (ISCOM), bacterial derivatives, carbo-
hydrate adjuvants, liposomes, cytokines, virus like particles
and polymeric microparticle adjuvants.
2.1.1. Mineral salts
Mineral salts such as alum and calcium phosphate have been
used as adjuvant in vaccine formulations. Glenney et al.
(1926) have demonstrated the addition of potassium alum to
diphtheria toxin resulted in a precipitate. The precipitated
diphtheria toxin when injected into guinea pigs resulted in a
higher number of antibody production when compared to nor-
mal non-precipitated diphtheria toxoid. Relyveld et al. (1985)
and Relyveld (1986) demonstrated calcium phosphate as vac-
cine adjuvant. Alum is chemically potassium aluminum sulfate
was initially used for purifying the protein antigen such as tet-
anus toxoid and diphtheria toxoid by precipitating them.
However, aluminum compounds used as vaccine adjuvants
are aluminum phosphate or aluminum hydroxide. In practicethe aluminum phosphate and aluminum hydroxide imperfectly
referred as alum but they have different physical characteristics
and differ in their adjuvant property. Among this, aluminum
hydroxide showed higher adsorption property and found to
be more potent than aluminum phosphate. Aluminum salts
are effective forming a short term depot (Table 1) at the site
of injection, slowly releasing antigen to the body’s immune re-
sponse system (Gupta et al., 1993, 1995). Since last 90 years,
various substances have been tried and used as vaccine adju-
vant, most of these substances were never accepted for human
vaccines due to their high level of toxicity and still the alum
salts remain the safest adjuvant approved by United States
Food Drug Administration (US FDA) for human vaccine
products (Gupta et al., 1995). But the use of aluminum adju-
vant in manufacturing vaccines is a difﬁcult task because the
adsorption of antigen on aluminum type adjuvant is based
on physico-chemical characteristics of antigen. Although, alu-
minum salts remain the only adjuvant approved for human use
it has some limitation such as lacking in inducing cyto toxic T-
lymphocyte (CTL) responses especially to protect from viral
infection (Doherty et al., 2006). Besides, there are well docu-
mented problems of aluminum adjuvant that induce inﬂamma-
tion and stimulate local production of erythema, granuloma,
subcutaneous nodules and contact hypersensitivity (Men
et al., 1995; Baylor et al., 2002) in addition to that alum cannot
be frozen or lyophilized. Walls (1977) and Nagel et al. (1977)
reported that aluminum hydroxide has attraction towards
eosinophil that leads IgE mediated allergic reaction at the site
of injection. On the other hand, Gupta et al. (1995) stated that
aluminum adjuvants have been used for many years for hypo-
sensitization of allergic patients without adverse effects.
Clements and Griffth (2002) reported that the alum has been
established as a safety adjuvant for vaccine delivery since last
90 years. Furthermore, aluminum consumption from vaccines
is far less than that received from the diet or medications such
as antacids (Baylor et al., 2002). Nonetheless, in recent years,
the adjuvants received much attention because of the develop-
ment of protein subunits made by rDNA technology (Hanes
et al., 1997). The sub unit vaccines are weakly immunogenic
when compared to whole-cell vaccines and therefore, need suit-
able adjuvants for delivering the antigens. Even though alum
has good properties it is not much suitable for small proteins
because the alum adsorbed vaccines elicit a short term immune
response requiring many boosters for attaining minimum opti-
mal threshold immune response. Consequently, it is necessary
to ﬁnd a new adjuvant that can replace the alum type adjuvant.
2.1.2. Oil emulsions
Le Moignic and Piony (1916) demonstrated that the suspen-
sion of killed Salmonella typhimurium with mineral oil emul-
sion elicited increased immune response. Later Freunds et al.
(1937) prepared a w/o type of emulsion adjuvant using parafﬁn
oil mixed with killed Mycobacteria called Freund’s complete
adjuvant (FCA) and without mycobacteria referred as Fre-
und’s incomplete Adjuvant (FIA). The FIA forms depot at
the site of injection (Table 2) and slow release of antigen with
the stimulation of antibody producing cells led to poor immu-
nomodulatory effect (Freund, 1956). Earlier, FIA was used in
human vaccine formulations such as inﬂuenza and killed polio-
myelitis vaccines (Davenport, 1968; Salk and Salk, 1977).
However, FIA is not currently used due to poor immunogenic
effect, induces local irritation, may cause granuloma and cyst
Table 1 Mineral adjuvants and their properties.
Adjuvant type Representing examples General description Mechanism of action Advantages Disadvantages
Mineral salts Aluminum salts –
aluminum hydroxide or
aluminum phosphate
1. Licensed and approved by US
FDA for human use
2. Misreferred as alum
3. It is widely used as human and
veterinary vaccines
4. Aluminum hydroxide is more
potent than aluminum phosphate
due to their adsorption property
5. Considered as the safest adjuvant
1. Sort term depot effect
2. Induction of cytokine
network
3. Complement activation
4. Delivery of antigens to differ-
ent APC
5. Strong Th2 response
1. In expensive
2. Safe
3. Efﬁcient uptake of alum
adsorbed antigens by antigen
presenting cells due to partic-
ulate nature with optimum
size
4. Long lasting immune
response when compared to
soluble antigens
1. Not suitable for recombinant proteins
and sub unit vaccines
2. Adverse effects have been reported
such as inﬂammation and stimulate
local production of erythema, granu-
loma, subcutaneous nodules, contact
hypersensitivity and IgE mediated
hypersensitivity. Alum cannot be fro-
zen or lypholized
3. Unable to induce cytotoxic T cell
response
Calcium salts 1. Calcium salts in the form of Cal-
cium phosphate have been used
as human vaccine adjuvant espe-
cially DTP, polio, yellow fever
and BCG vaccines
2. Approved for human use in Euro-
pean countries
1. Short term depot effect
2. Adsorbs soluble antigens and
presents them in a particulate
form to the immune system
It is a normal constituent of the
body and therefore well
tolerated, elicit high IgG type
antibodies
1. It lacks immunomodulatory response
2. Neurological reactions have been
observed
3. Local irritation and active inﬂamma-
tory reaction at the site of injection
Table 2 Properties of oil emulsion and microbial derivatives as vaccine adjuvant.
Adjuvant type Representing examples General description Mechanism of action Advantages Disadvantages
Oil emulsion Freund’s complete
adjuvant (FCA)
w/o type of emulsion adjuvant using
paraﬃn oil mixed with killed
Mycobacteria
1. Short term depot effect
2. Strong Th1 and Th2 response
by producing
Strong immune response Highly toxic
Freund’s incomplete
adjuvant (FIA)
w/o type of emulsion adjuvant using
paraﬃn oil mixed without killed
Mycobacteria
1. Short term depot
2. It induces weak Th1 and Th2
response
Lesser side eﬀects than FCA 1. Poor immunomodulatory effect
2. Local irritant effect may induce
granuloma and cyst formation
MF 59 1. o/w type emulsion contains 4.3% of
squalene oil, tween 80 and span 85
2. Licensed for human use in European
countries
Inducing local immune
stimulatory eﬀect at the site of
injection, regulates cytokines,
chemokines, recruitment of
CD11b+, MHC II+ cells and
enhance antigen uptake by
dendritic cells
It is a superior than alum
adjuvant for inﬂuenza vaccine
1. Pain at injection site
2. Reactogenicity
3. Induces inﬂammatory arthritis
Microbial
derivatives
ASO4 1. It is 3-O-desacyl-40-monophosphoryl
lipid A obtained from the cell wall
LPS of Gram-negative Salmonella
minnesota R595
2. Licensed for human use in European
countries
Local activation of NF-kB
activity, cytokine production,
optimal activation of APC and
generation of Th1 response
It is superior than alum adjuvant
for cancer, HBV, malaria and
HPV
1. Reactogenicity
2. Issues on consistency of prepara-
tion of vaccines from bacteria
3. Cost effective
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Vaccine adjuvants – Current status and prospectson controlled release adjuvancity 201formation at the site of injection and reported carcinogenic in
mice (Murray et al., 1972; Potter and Boyce, 1962; Gupta
et al., 1993). The FCA can induce strong Th1 and Th2 immune
response because of the combination of Mycobacterium tuber-
culosis with w/o type of emulsion (Freund et al., 1948). How-
ever, inducing toxic effect is the major disadvantage of this
adjuvant. There are some other oil emulsions which have also
been demonstrated adjuvant properties include Montanide
(Aucouturier et al., 2002), Adjuvant 65 (Hilleman et al.,
1972; Weibel et al., 1973) and Lipovant (Byars and Allison,
1990). But these adjuvants are also not much useful for routine
human prophylactic vaccine because of their toxic properties
(Aguilar and Rodriguez, 2007). MF 59 is an adjuvant devel-
oped by the ex-Chiron now Novartis Vaccines (O’Hagan
et al., 2007) consists of oil-in-water emulsion (Table 2), com-
prising 4.3% of squalene oil as dispersed phase, which is stabi-
lized by two non-ionic surfactants (Tween 80 and Span 85),
and a low ionic strength citrate buffers as continuous phase.
MF 59 is originally developed as delivery agent that contains
muramyl tripeptide phosphatidylethanolamine (MTP-PE),
which activates non-TLR sensing receptors known as NOD
LRRs (Akira et al., 2006) that leads toxicity. But the MF 59
without MTP-PE proved as a potent adjuvant for inﬂuenza
vaccine (Fluad) tested in animal model and later human trials
have been shown successful results. Thus it becomes ﬁrst new
adjuvant for human use after alum (Tagliabue and Rappuoli,
2008).
2.1.3. Immune stimulating complexes (ISCOM)
The immune stimulating complexes (ISCOMs) were ﬁrst de-
scribed by Morein et al. (1984). ISCOM and ISCOMs
(Table 3) are trade marks of ISOTEC AB, Uppsala, Sweden
that composed of saponin, cholesterol, phospholipid and
immunogen (Sjolander et al., 1998). Saponin such as Quil A
has also been used as a component of immune stimulating
complexes (Kensil, 1996). Quil A is a triterpenoid saponins ob-
tained from Quillaia saponins is less toxic than crude saponins
(Dalsgaard, 1978; Dalsgaard et al., 1990). Quil A was not sat-
isfactory for human use because it is a heterogeneous mixture
of many closely related saponins that vary in their chem-
ical and biological activities lead to unpredictable effects
(Sjolander et al., 1998). QS-21 is a puriﬁed form of crude ex-
tracts of Quil A have the ability to induce strong cellular im-
mune response against various pathogen derived antigens and
HIV-1 (Allison and Byars, 1991; Takahashi et al., 1990). QS-
21 is less toxic when compared to Quil A but it has same toxic
properties of Quil A that leads to unsuitable for human uses
other than cancer vaccines where higher toxicity may be ac-
cepted (Kensil et al., 1995).
2.1.4. Bacterial derivatives
Bacterial toxins and toxoids from Escherichia coli and Vibrio
cholera have been reported as mucosal adjuvants (Walker,
1994; McGhee et al., 1992). Bacterial cell wall components like
peptidoglycan or lipopolysaccahrides (LPS) enhance the im-
mune response by mediating through activation of Toll-like
receptors (TLR) that activates the host immune system
(Audibert and Lise, 1993). LPS containing the active lipid A
moiety can act as potent mucosal adjuvants but it is too toxic
for human vaccines. GlaxoSmithKline developed an adju-
vant ASO4 contains 3-O-desacyl-40-monophosphoryl lipid A
(MPL) that obtained from the cell wall LPS of Gram-negative
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treatment andpuriﬁcation (Table 2).ASO4 is absorbed on either
aluminum hydroxide or aluminum phosphate and it became
second new adjuvant for human use afterMF 59. Recently, a re-
combinant hepatitis B vaccine (FEN-Drix) has been formulated
with ASO4 and compared their efﬁcacy with Energix-B in
healthy young adults (Levie et al., 2002) of European region.
Cerevarix is a vaccine against human papilloma virus, a causa-
tive agent of cervical cancer is formulated with ASO4 to prove
high and sustained level of antibodies aimed to provide long
term protection. ASO3 is also an adjuvant developed by
GlaxoSmithKline contains squalene. It is used as an adjuvant
for swine ﬂu vaccine being used in Canada and Europe.
2.1.5. Carbohydrate adjuvants
Several complex carbohydrates of natural origin such as gam-
ma inulin derived from plant root of the composite family
stimulate both humoral and cellular immunity. It activates
complement pathway and increases the production of acti-
vated C3 and thereby activating macrophages (Cooper,
1995). Gamma inulin can be combined with variety of other
adjuvants to get a better adjuvant, for example algammulin.
Algammulin is a combination of Gamma inulin with alumi-
num hydroxide a potent inducer of Th1 and Th2 activity when
compared to gamma inulin alone (Cooper et al., 1991; Cooper
and Steele, 1991). Inulin can be easily metabolized in to simple
sugars fructose and glucose and does not suffer from the ad-
verse effects that are associated with alum based adjuvants
(Petrovsky and Aguilar, 2004). Other polysaccharides such as
glucans, dextrans, glucomannons, galactomannans, levans
and xylans (Tizard et al., 1989; Sheets et al., 1991) also en-
hance the immune response.
2.1.6. Liposomes
Liposomes are synthetic spheres containing lipid layers that
can encapsulate antigens that are desired and act as adjuvants
(Table 3). Liposomes can induce both humoral and cellular
immunity to protein and polysaccharide antigens (Allison
and Gregoriadis, 1974; Rooijen and Nieuwmegen, 1983). The
potency of liposomes varies with the number of lipid layers
(Shek et al., 1983), electric charge (Allison and Gregoriadis,
1974), composition and method of preparation (Heath et al.,
1976; Tyrrel et al., 1976). Liposome based hepatitis A vaccine
(Epaxal) was developed by Swiss Serum and Vaccine Institute
(Ambrosch et al., 1997) demonstrated that two doses of the
liposomal hepatitis A vaccine administered at months 0 and
12 early protection within 14 days and long lasting immunity
can be attained. The liposomal based vaccines fuse with cell
membranes of macrophages, enabling the delivery of proteins
into the cytoplasm and enter in to MHC class I pathway and
activate CD8 cells (Owis and Gupta, 2000; Zheng et al.,
1999). The major drawbacks of liposomes are manufacturing
difﬁculties such as stability, high cost and may produce pain
at the site of injection.
2.1.7. Cytokines
Cytokines are low molecular weight soluble proteins that are
formed in response to antigens and regulate the innate and
adaptive immune response. Cytokines are grouped in the mod-
ern classiﬁcation of adjuvants for example Granulocyte–
macrophage colony stimulating factor (GM-CSF) enhances
the primary immune response by stimulating and activatingthe antigen presenting the cells (Heuﬂer et al., 1988). Cytokines
are much useful only in cancer vaccines but its application is
limited due to toxicity.
2.1.8. Virus like particles (VLP)
Viruses like particles are inert, empty capsids of viruses that
lack nuclear material but retain the structure of a virus. By
means of genetic engineering technology the desired antigens
can be attached to VLP. The VLP presents the antigens are
capably engaged by dendritic cells that induce strong immune
response (Antonis et al., 2006; Young et al., 2006; Dell et al.,
2006). Recombinant hepatitis B surface antigen (HBsAg) has
been produced as VLPs in Saccharomyces cerevisiae. Recently
human papilloma virus vaccine has been produced by this VLP
technology and approved by US Food and Drug Administra-
tion for clinical use (Aguilar and Rodriguez, 2007).
2.1.9. Polymeric microparticle adjuvants
Biodegradable polymers are being used as sutures and drug
carriers, because of the biocompatible, nontoxic nature and
their biodegradable properties. The polymers which are chosen
as excipients (adjuvants) for parenterally administered vac-
cines should meet some of the requirements, including being
biodegradable, safe (tissue compatible, no secondary reaction),
antigen compatible and permeable, stable in vitro easy to pro-
cess, alone responsible formulations and ideally inexpensive.
The biodegradable synthetic and natural polymers have been
investigated for the control release of macromolecular drugs
and proteins. These polymers in the form of microspheres/
microparticles seem to be preferred for better controlled re-
lease of antigen (Table 3). Novel vaccines based on recombi-
nant proteins and DNA, are safer than traditional vaccines,
but they are unfortunately less immunogenic. Therefore, there
is an urgent need for the development of potent, safe adjuvants
as delivery systems that can be used to boost up the immune
response of vaccines. In recent years a great effort has been
made to improve the efﬁcacy of vaccine by using novel adju-
vant or antigen carrier as delivery systems.
Polymer microspheres are solid, spherical or approximately
spherical particles ranging in size from 1 to 1000 lm. Micro-
sphere-based antigen deliver systems can now be made to deli-
ver subunit protein and peptide antigens in their native form in
a continuous or pulsatile fashion for periods ranging from
weeks to months. Polymer microspheres have shown great po-
tential as a next generation adjuvant to replace or complement
existing aluminum salts for vaccine potentiation. The use of
polymers to control the release of an antigen to stimulate the
immune response was ﬁrst reported by Peris and Langer
(1979). Controlled release of antigens from polymer micropar-
ticles has been of great interest to the development of vaccine
adjuvant which could be effective in a single dose (single-step
immunization). Controlled vaccine delivery system signiﬁcantly
enhances immunity without invoking a vigorous inﬂammatory
response. But instead it follows a phenomenon known as depot
therapy. In fact, controlled release systems can provide a re-
lease of antigens for weeks to months, a time far exceeding
the depot effect of aluminum salts or w/o emulsions such as
Freund’s adjuvants. In addition, the prolonged and pulsatile re-
lease of vaccine from microparticles may mimic the priming
and boosting effect of conventional vaccines. The antigen re-
leased from microparticles could regulate the desired immuno-
logical effect. However, the release rate is greatly inﬂuenced by
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and the porosity of microparticles (adjuvants).
Poly(D,L-lactide-co-glycolic acid) is a polymer ester of the
two hydroxyl acids, viz., lactic and glycolic acids. PLGA de-
grades through bulk erosion by hydrolysis of its ester linkages
in the presence of water, which gives lactic acid and glycolic
acid. These two monomers under normal physiological condi-
tions are byproducts of various metabolic pathways in the
body. Therefore, the human body effectively deals with these
monomers, which can be metabolized via the TCA cycle. It
is approved by food and drug administration, United States
for therapeutic devices for many years as resorbable sutures
and bone plates (Austin et al., 1995; Pihlajamaki et al., 1992;
Winde et al., 1993).
Maria Alonso et al. (1999) developed a single dose tetanus
vaccine based on poly(lactide-co-glycolic acid) microspheres,
which became complicated because of instability of tetanus
toxoid. They attempted to redesign PLGA microspheres by
co-encapsulating together with tetanus toxoid in dry solid state
together with potential stabilizers such as the haloes, bovine ser-
um albumin, alginate, heparin, dextran or poloxamer 188 by
employing an appropriate technique. The PLGA microspheres
were able to release in vitro antigenically active tetanus toxoid
for at least 5 weeks. The efﬁcacy of the strategy was demon-
strated by high, long lasting, titers of neutralizing antibodies
achieved after in vivo administration of dextran containing
microspheres with a fraction of alum adsorbed tetanus toxoid
as compared to the commercial absorbable tetanus toxoid vac-
cine. These ﬁndings suggest that future developments in the area
of vaccinology depend on the ability to combine a detailed
knowledge of the microencapsulation technology with rational
choice of stabilizing excipient or combination of excipients.
Feng et al. (2006) investigated that the feasibility of a sin-
gle-dose hepatitis B vaccine based on three kinds of PLGA
microspheres. PLGA microspheres loaded with recombinant
hepatitis B surface antigen (HBsAg) were formulated using a
double emulsion microencapsulation technique. The pharma-
ceutical characteristics of size, surface morphology, loading
efﬁciency, antigen integrity and release from PLGA micro-
spheres and their in vitro degradation were evaluated. The deg-
radation of the polymer corresponded with the composition of
the polymer (lactide/glycolide ratio), molecular weight of the
polymer (viscosity) and morphology of the microspheres, were
able to continuously release antigen under conditions that mi-
mic the environment in vivo. The single subcutaneous injection
of HBsAg-loaded PLGA 50/50 microspheres, PLGA 75/25
microspheres and a mixture of PLGA 50/50, PLGA 75/25,
and PLGA 50/50-COOH microspheres in mice resulted in
comparable serum antibody titers to those of three injections
of the conventional aluminum adjuvant formulated HBsAg
vaccine. Based on these ﬁndings in vitro and in vivo, it was con-
cluded that HBsAg was successfully loaded into the PLGA
microspheres, which can auto-boost an immune response,
and the HBsAg-loaded PLGA microsphere is a promising can-
didate for the controlled delivery of a vaccine. Poly(lactic acid)
(PLA) is biodegradable, biocompatible, thermoplastic, ali-
phatic polyester derived from lactic acid. It is frequently used
in bone repair applications. The polymer chains are cleaved
by hydrolysis to form monomeric acids and are eliminated
from the body through Krebs’s cycle, as carbon dioxide
through respiration and water in urine. The rate of hydrolysis
of the polymer chain is dependent on signiﬁcant temperature,pH or presence of catalyst. The utilization of PLA as sustained
release vaccine carrier system was demonstrated by some
researchers (Sivakumar et al., 2010).
Chitosan is a natural polymer has great potential for phar-
maceutical applications due to its biocompatibility, biodegrad-
ability, high charge density and non-toxicity (Sinha et al.,
2004). It also has antacid and anti-ulcer activities (Ito et al.,
2000), wound healing properties (Tachihara et al., 1997); it is
also used in artiﬁcial kidney membranes because of their suit-
able permeability and high tensile strength (Amiji, 1995).
Chitosan has been used as a vehicle for directly compressed
tablets (Kristmundsdoittr et al., 1995). Chitosan microspheres
are widely studied drug delivery system for the controlled re-
lease of drugs such as antibiotics, anti-cancer agents, proteins
and vaccines. Vaccine research is often focused to ﬁnd out no-
vel antigens, their delivery methods, including variation of
adjuvants used, the dose and number of injections (Lofthouse,
2002). Many classical adjuvants such as bacterial cell wall ex-
tracts are having adjuvant properties and can stimulate non-
speciﬁc inﬂammatory response (Hanes et al., 1997). The ability
of chitosan to enhance both the systemic and local immune re-
sponses against diphtheria toxoid after oral and nasal admin-
istration was demonstrated by Vander Lubben et al. (2003).
DT associated to chitosan microparticles resulted in systemic
humoral and local immune responses against DT oral vaccina-
tion and insigniﬁcant enhancement of IgG production after
nasal administration. Hence these experiments demonstrated
that chitosan microparticles were very promising mucosal
delivery system. Tiyaboonchai and Nanteetip (2007) fabricated
a new nanoparticulate delivery system for amphotericin B. In
their work, two opposite charged polymers were used to form
nanoparticles through electrostatic interaction, chitosan a pos-
itively charged particle and dextran sulfate a negatively
charged polymer linked together and hardened by zinc sulfate.
The importance of developing new vaccine systems with
proper attention to developing controlled delivery system
was demonstrated by Stanley Davis (2006). They stated poly-
mer microspheres and lamellar particle based on the biode-
gradable materials PLA and PLGA could be employed for
the improved parenteral and mucosal administration of anti-
gens. Like wise soluble biopolymers such as chitosan could
be used for the nasal delivery of various antigens as well as
DNA. The process of optimization is one of the most impor-
tant biological barriers to controlled drug delivery (Donald
Owens and Nicholas Peppas, 2006). Sangmook and Jae Wook
(2005) investigated the thermal, rheological, morphological
and mechanical properties of a binary blend of poly(lactic
acid) and poly(butylenes succinate adipate). Yong-Hong
et al. (2005) investigated the physical stability of spray dried
proteins with surfactant free hydroﬂuroalkane pressurised me-
tered dose inhalers during prolonged storage. The results indi-
cated that the presence of PVA in the spray dried stabilized
protein particles could enhance the physical stability of micro-
particles. Recently chitosan microspheres have been demon-
strated as better adjuvant for HBsAg when compared to
PLGA and PLA (Sivakumar et al., 2010).3. Vaccine encapsulated microspheres and immune response
Potent adjuvants can improve the efﬁcacy of vaccines by
inducing robust immune responses for longer duration.
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cessing through their ability to target phagocytosis by antigen
presenting cells (APCs). The encapsulation of antigen in a bio-
degradable polymer particulate system or on their surface
adsorption can lead to antigen presentation by MHC class I
pathway (Men et al., 1995; Moore et al., 1995; Nixon et al.,
1996; Bandowiski et al., 1993; Falo et al., 1995; Rock and
Clark, 1996). The important function of MHC class I molecule
is bind to the processed endogenous antigen and present it to
the immunocompetent cells that lead to cytotoxic T lympho-
cyte (CTL)-mediated immune response. Presentation of anti-
gen to the immunocompetent cells by MHC class II molecule
generally leads to enhanced antibody production, i.e., induc-
tion of humoral immune response.
The biodegradable polymer microspheres form depot that
retains antigens for an extended period and exposing towards
the immune system for longer duration. Early reports showed
that the interaction between antigen and the cells of the drain-
ing lymph node is one of the basic parameters that determine
the outcome of any immune response (Zinkernagel et al., 1997;
Zinkernagel, 2000). On the other hand, the duration of anti-
genic stimulus has been demonstrated by various scientists
and suggested that the continuous release of antigen is a major
factor for determining the fate of both naı¨ve and effector T
cells. Naı¨ve T cells require prolonged signaling for at least
2 h (Iezzi et al., 1998) and up to 2–3 days (Zinkernagel,
2000) to become committed to proliferation, while effector T
cells require only 1 h of antigen stimulation (Iezzi et al.,
1998) but prolonged stimulation may induce death of effector
cells (Cleland, 1999). It is noted that low dose of i.v. injections
has been shown to induce immunity where as high dose in i.v.
results immunotolerance (Zinkernagel et al., 1997). Earlier re-
ports showed that a mature immune response can be induced
by continuous antigen delivery and lead to extended effector
responses but the activation of immune memory requires boos-
ter stimulation with antigen (Lofthouse, 2002). However, pul-
satile delivery of antigen has been stimulated through the use
of microencapsulated vaccines in biodegradable polymers that
vary in density or size (Cleland, 1999; Sanchez et al., 1996).
Although there is a number of a biological and synthetic poly-
mer available for use in microencapsulation, a vaccine formu-
lation intended for human requires the use of biodegradable
polymers and their safety is an important parameter. Micro-
spheres are capable of protecting the vaccine and presenting
in its native conformation to the various cells of the immune
system. The need of improved method of delivering antigens
has spurred research aimed at the development of future gen-
eration adjuvants. The signiﬁcance of stable antigen delivery
from microspheres has been highlighted by an enormous num-
ber of investigators. Therefore, the development of newer vac-
cine delivery system, both efﬁcacious and easier to deliver has
an area of research that can certainly beneﬁt from controlled
release technology.4. Conclusion
Prevention of diseases through immunization programme is
the most cost effective health arbitration. Alum, MF 59 and
ASO4 are the adjuvants used in vaccine formulation for hu-
man usage but requires multiple dose regimens. The develop-
ment of single contact vaccines mainly administered soonafter birth to combat various infections will be an important
advancement towards the betterment of human health care.
Though many reports proved that microspheres based vaccines
provide a long term antigen release by forming a depot at the
site of injection, and target the antigen presenting cells leading
to the enhancement of humoral or cell mediated immunity.
Unfortunately it is not applicable in practice till date and it
is under study level only. Let us hope for the best in future
to get a better adjuvant for vaccine delivery to develop single
contact vaccines.References
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